The Informed Choice quality assurance program from LGC has extended its product offering to CBD and hemp product certification.
The Informed Choice quality assurance program from LGC has extended its product offering to CBD and hemp product certification. The cannabinoid product certification was developed to provide label accuracy to consumers. For example, delta-9 THC content in these products is particularly important. Delta-9 THC is the intoxicating component of cannabis associated with recreational marijuana consumption. By contrast, hemp has a lower delta-9 THC content and legally, in the U.S., hemp and its derivatives are defined as having 0.3% of THC or less by dry weight. Many consumers also don’t want the intoxicating effects of THC or risk failing a workplace drug test.
Therefore, in addition to testing the CBD content of products, Informed Choice requires CBD and other hemp-derived products to undergo testing for delta-9 THC. Brands will be required to provide serving information which will be used to determine the daily consumption of delta-9 THC and in order to be certified and comply, each batch must have a consumption limit of less than 0.083 mg per day.
Certified CBD and hemp-derived products will carry the Informed Choice logo on product packaging and will be listed on the Informed Choice website along with all tested batch numbers. “With ongoing supply chain issues facing the industry and increased consumer interest in CBD / hemp-derived products, reputable companies can utilize this certification to demonstrate their commitment to quality assurance,” said Paul Klinger, director of Informed Business Development, in a press release. “Certification also sets brands apart from the growing competition within the cannabinoid product industry. When a customer sees the Informed Choice logo on a product, they can have confidence that the CBD and [delta]9-THC content have been independently verified and the product has undergone rigorous testing for potentially harmful substances.”
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.